Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Mitchell, E. P.
Lacouture, M.
Shearer, H.
Iannotti, N.
Piperdi, B.
Pillai, M.
Xu, F.
Yassine, M.
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[2] Northwestern Univ, Chicago, IL 60611 USA
[3] Piedmont Hematol Oncol Associates PLLC, Winston Salem, NC USA
[4] Hematol Oncol Associates Treasure Coast, Port St Lucie, FL USA
[5] Univ Massachusetts, Med Ctr, Worcester, MA USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4027
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC)
    Mitchell, E. P.
    Lacouture, M.
    Shearer, H.
    Iannotti, N.
    Piperdi, B.
    Pillai, M.
    Xu, F.
    Yassine, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [2] Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST)
    Price, T. J.
    Sobrero, A. F.
    Wilson, G.
    Van Cutsem, E.
    Aleknaviciene, B.
    Zaniboni, A.
    Hartmann, J. T.
    Tian, Y.
    Gansert, J. L.
    Peeters, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A phase II, open-label trial of skin toxicity (ST) evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving panitumumab (pmab) plus FOLFIRI or irinotecan-only chemotherapy (CT) as 2nd-line treatment (tx): Interim analysis
    Mitchell, E. P.
    LaCouture, M. E.
    Shearer, H.
    Iannotti, N.
    Piperdi, B.
    Pillai, M. V.
    Xu, F.
    Couture, M.
    Yassine, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results
    Peeters, M.
    Wilson, G.
    Ducreux, M.
    Cervantes, A.
    Andre, T.
    Hotko, Y.
    Lordick, F.
    Collins, S.
    Shing, M.
    Price, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results
    Rougier, P.
    Infante, J.
    Van Laethem, J.
    Stephenson, J. J.
    Uronis, H.
    Schwartzberg, L.
    Chen, L.
    Wu, C.
    Smethurst, D.
    Peeters, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second -line treatment (tx) of metastatic colorectal cancer (mCRC)
    Sobrero, Alberto F.
    Peeters, Marc
    Price, Timothy Jay
    Hotko, Yevhen
    Cervantes-Ruiperez, Andres
    Ducreux, Michel
    Andre, Thierry
    Chan, Emily
    Lordick, Florian
    Tian, Ying
    Sidhu, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST)
    Douillard, J.
    Cassidy, J.
    Jassem, J.
    Rivera, F.
    Kocakova, I.
    Rogowski, W.
    Canon, J. R.
    Yanez, E. P.
    Xu, F.
    Gansert, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Panitumumab (pmab) in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC): Final analysis from a community-based, observational study (VECTOR) in Germany
    Lerchenmuller, Christian A.
    Groschek, Matthias
    Kroening, Hendrik
    Scheuer, Burkhard
    Stauch, Martina
    Kuhn, Anja
    Hellebrand, Eva
    Vehling-Kaiser, Ursula
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [9] Panitumumab (pmab) plus AMG 102 in patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Updated safety results
    Eng, C.
    Tabernero, J.
    Nowara, E.
    Swieboda-Sadlej, A.
    Tebbutt, N. C.
    Mitchell, E. P.
    Davidenko, I.
    Chen, L.
    Smethurst, D.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts)
    Hendlisz, A.
    Van Cutsem, E.
    Peeters, M.
    Humblet, Y.
    Neyns, B.
    Sobrero, A.
    Devercelli, G.
    Wolf, M.
    Amado, R. G.
    Siena, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345